Hexarelin

Description

EP-23905 (Hexarelin) Overview

EP-23905 Acetate, also known as Hexarelin, is a synthetic hexapeptide investigated in laboratory research involving the growth hormone secretagogue receptor (GHS-R1a).

It belongs to a class of investigational peptides commonly examined for their interaction with ghrelin-related receptor systems and endocrine signaling pathways.

In biochemical and molecular studies, EP-23905 is often explored to understand how peptide compounds influence receptor activation and intracellular communication mechanisms. These investigations are typically performed in controlled experimental settings.

What Is GHS-R1a?

Growth hormone secretagogue receptor type 1a (GHS-R1a) is a G protein-coupled receptor (GPCR) that serves as the primary receptor for ghrelin and synthetic growth hormone secretagogues such as Hexarelin (EP-23905). Researchers study GHS-R1a to better understand receptor activation, intracellular signaling, and endocrine-related regulatory pathways in experimental models.

Why Is Hexarelin Used in Research?

Hexarelin is primarily investigated as a synthetic growth hormone secretagogue in laboratory research. Experimental studies examine its interaction with GHS-R1a, receptor pharmacology, intracellular signaling mechanisms, and peptide-mediated endocrine pathways under controlled research conditions.

How Does Hexarelin Differ from Ghrelin?

Although both compounds interact with GHS-R1a, ghrelin is a naturally occurring peptide hormone, whereas Hexarelin is a synthetic hexapeptide developed for research. Unlike ghrelin, Hexarelin does not require octanoylation for receptor activity and is commonly studied because of its improved chemical stability and receptor-binding characteristics in experimental settings.

Proposed GHS-R1a Receptor Interaction Mechanism

EP-23905 has been investigated for potential binding to the growth hormone secretagogue receptor (GHS-R1a). It's a receptor commonly examined in research involving ghrelin-related signaling pathways.

Experimental studies suggest that activation of GHS-R1a may stimulate intracellular signaling pathways including phospholipase C (PLC), intracellular calcium mobilization, protein kinase C (PKC), and mitogen-activated protein kinase (MAPK), although pathway activation varies according to cell type and experimental conditions.

Possible Research Applications of EP-23905 Acetate

Experimental investigations primarily examine receptor pharmacology, intracellular signaling, endocrine regulation, and GHS-R-mediated cellular responses under controlled laboratory conditions.

Though more advanced research is required, some research applications focus on:

• Binding interactions with growth hormone secretagogue receptors
• Cellular signaling pathways associated with ghrelin-related receptor systems
• Peptide-mediated intracellular signaling processes
• intracellular signaling within hormone-related regulatory pathways

Chemical Properties of EP-23905

Property	Description
Compound Name	EP-23905
Chemical Class	Synthetic Growth Hormone Secretagogue (GHS)
Molecular Formula	C47H58N12O6
Molecular Weight	887.05 g/mol
CAS Number	140703-51-1
Peptide Length	Hexapeptide
Synonyms	EP-23905, Hexarelin
IUPAC	(2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide

Why Buy EP-23905 at Purerawz?

Purerawz provides research materials intended for laboratory and analytical applications. Batch-specific analytical documentation, including testing data for compound identity and purity, is available where applicable to support research verification.

Please note that this compound is not FDA-approved and is not intended for human consumption. For additional information, please contact support@purerawz.co.

FAQs

What makes EP-23905 different from other research peptides?

EP-23905 is primarily studied for its potential interaction with growth hormone secretagogue receptor pathways, making it a compound of interest in peptide-receptor and endocrine signaling research.

How Is EP-23905 Characterized?

Research-grade EP-23905 (Hexarelin) is typically characterized using multiple analytical techniques. RP-HPLC is commonly used to estimate chromatographic purity, while LC-MS supports molecular weight verification and peptide identity confirmation. Researchers generally evaluate these analytical results together with batch-specific quality documentation to assess research-grade material.

Why Does Peptide Purity Matter for EP-23905?

Peptide purity helps researchers evaluate the proportion of the target peptide relative to detectable impurities. Higher chromatographic purity may reduce experimental variability caused by peptide-related impurities, although purity should be interpreted alongside identity confirmation and analytical documentation.

Why Is a Batch-Specific Certificate of Analysis (COA) Important?

A batch-specific Certificate of Analysis (COA) provides analytical data for the exact production lot of EP-23905. Researchers commonly review the COA to verify RP-HPLC purity, LC-MS identity confirmation, batch number, and other quality-control information before laboratory use.

Why is receptor-binding research important for peptides like EP-23905?

Receptor-binding studies help researchers understand how synthetic peptides may influence cellular communication, signaling cascades, and downstream biochemical responses.

Can EP-23905 be used in endocrine-related studies?

EP-23905 has been investigated in experimental models examining GHS-R-mediated endocrine signaling and peptide-receptor interactions. Its suitability depends on the objectives and design of individual research protocols.

What factors should researchers consider before purchasing EP-23905?

Researchers should review product specifications, analytical documentation, purity data, and storage requirements to ensure suitability for their experimental needs.

Disclaimer

This information is for educational purposes only and not medical advice. Products are for research use only. Research must follow IRB or IACUC guidelines. Verify information independently before purchasing. By ordering, you agree to our Terms and Conditions. 

Please know that this compound is not FDA-approved and is not considered for human consumption. For more information, please contact us at support@purerawz.co 

Reference Links

• Waddingham, M. T., Tsuchimochi, H., Sonobe, T., Asano, R., Jin, H., Ow, C. P. C., Schwenke, D. O., Katare, R., Aoyama, K., Umetani, K., Hoshino, M., Uesugi, K., Shirai, M., Ogo, T., & Pearson, J. T. (2022). Using synchrotron radiation imaging techniques to elucidate the actions of hexarelin in the heart of small animal models. Frontiers in Physiology, 12, 766818. https://doi.org/10.3389/fphys.2021.766818
• Huang, Z., Lu, X., Huang, L., Zhang, C., Veldhuis, J. D., Cowley, M. A., & Chen, C. (2021). Stimulation of endogenous pulsatile growth hormone secretion by activation of growth hormone secretagogue receptor reduces the fat accumulation and improves the insulin sensitivity in obese mice. The FASEB Journal, 35(1), e21269. https://doi.org/10.1096/fj.202001924RR
• Cheng, X.-L., Ding, F., Wang, D.-P., Zhou, L., & Cao, J.-M. (2019). Hexarelin attenuates atherosclerosis via inhibiting LOX-1-NF-κB signaling pathway-mediated macrophage ox-LDL uptake in ApoE⁻/⁻ mice. Peptides, 121, 170122. https://doi.org/10.1016/j.peptides.2019.170122
• Mosa, R., Huang, L., Wu, Y., Fung, C., Mallawakankanamalage, O., LeRoith, D., & Chen, C. (2017). Hexarelin, a growth hormone secretagogue, improves lipid metabolic aberrations in nonobese insulin-resistant male MKR mice. Endocrinology, 158(10), 3174–3187. https://doi.org/10.1210/en.2017-00168 (Co-authored with a researcher from the National Institute of Diabetes and Digestive and Kidney Diseases, NIH.)
• Huang, J., Li, Y., Zhang, J., Liu, Y., & Lu, Q. (2017). The growth hormone secretagogue hexarelin protects rat cardiomyocytes from in vivo ischemia/reperfusion injury through interleukin-1 signaling pathway. International Heart Journal, 58(2), 257–263. https://doi.org/10.1536/ihj.16-241
• üller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J, et al. (2015). Ghrelin. Molecular Metabolism, 4(6), 437–460. https://doi.org/10.1016/j.molmet.2015.03.005
• John, H., Walden, M., Schäfer, S., Genz, S., & Forssmann, W. G. (2004). Analytical procedures for quantification of peptides in pharmaceutical research by liquid chromatography-mass spectrometry. Analytical and Bioanalytical Chemistry, 378(4), 883–897. https://doi.org/10.1007/s00216-003-2298-y